tilpisertib fosmecarbil (GS-5290)
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 19, 2024
PALEKONA: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
(clinicaltrials.gov)
- P2 | N=176 | Recruiting | Sponsor: Gilead Sciences | Trial completion date: Jun 2026 ➔ May 2027 | Trial primary completion date: Jun 2025 ➔ Apr 2026
Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
December 01, 2023
PALEKONA: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
(clinicaltrials.gov)
- P2 | N=176 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting
Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
September 08, 2023
PALEKONA: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
(clinicaltrials.gov)
- P2 | N=176 | Not yet recruiting | Sponsor: Gilead Sciences
New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 3
Of
3
Go to page
1